Journal Watch · Frontiers in Immunology · 2026
Macrophage NPM1 drives anti-tumor immunity via the STAT3-CCRL2 axis.
Overexpression of <i>Npm1</i> in mice suppressed tumor growth, reduced M2 TAMs polarization, and enhanced CD8<sup>+</sup> T cell-mediated anti-tumor immunity.<h4>Conclusion</h4>Our findings revealed that NPM1 protects against tumor progression by regulating TAMs polarization and T cell function via the STAT3-CCRL2 axis.
TL;DR
Overexpression of <i>Npm1</i> in mice suppressed tumor growth, reduced M2 TAMs polarization, and enhanced CD8<sup>+</sup> T cell-mediated anti-tumor immunity.<h4>Conclusion</h4>Our findings revealed that NPM1 protects against tumor progression by regulating TAMs polarization and T cell function via the STAT3-CCRL2 axis.
Key findings
- Mechanistically, NPM1 bound to p-TAT3/STAT3 and promoted transcription of CCRL2, a key regulator of macrophage polarization.
- Overexpression of <i>Npm1</i> in mice suppressed tumor growth, reduced M2 TAMs polarization, and enhanced CD8<sup>+</sup> T cell-mediated anti-tumor immunity.<h4>Conclusion</h4>Our findings revealed that NPM1 protects against tumor progression by regulating TAMs polarization and T cell function via the STAT3-CCRL2 axis.
What they did
Here, we examined the function of NPM1 in regulating anti-tumor immunity within the tumor microenvironment.<h4>Methods</h4>The proportion and functional changes of macrophages and T cells were detected by flow cytometry, the downstream regulatory genes of <i>NPM1</i> were detected by RNA-seq, the binding ability of NPM1 and STAT3 was analyzed by Chip and luciferase assay.<h4>Results</h4>NPM1 inhibition or genetic deficiency promoted tumor growth in MC38 colon cancer and LLC lung cancer mice models. <i>Npm1<sup>+/-</sup></i> mice exhibited enhanced infiltration and polarization of immunosuppressive M2-like tumor-associated macrophages (TAMs) and impaired CD8<sup>+</sup> T cell function.
Full abstract (original)
Background: <h4>Background</h4>Although nucleophosmin (NPM1) is a well-characterized oncogene in acute myeloid leukemia, much less is known about its role in solid tumor immunity.
What they did: Here, we examined the function of NPM1 in regulating anti-tumor immunity within the tumor microenvironment.<h4>Methods</h4>The proportion and functional changes of macrophages and T cells were detected by flow cytometry, the downstream regulatory genes of <i>NPM1</i> were detected by RNA-seq, the binding ability of NPM1 and STAT3 was analyzed by Chip and luciferase assay.<h4>Results</h4>NPM1 inhibition or genetic deficiency promoted tumor growth in MC38 colon cancer and LLC lung cancer mice models. <i>Npm1<sup>+/-</sup></i> mice exhibited enhanced infiltration and polarization of immunosuppressive M2-like tumor-associated macrophages (TAMs) and impaired CD8<sup>+</sup> T cell function.
Results & conclusions: Mechanistically, NPM1 bound to p-TAT3/STAT3 and promoted transcription of CCRL2, a key regulator of macrophage polarization. Overexpression of <i>Npm1</i> in mice suppressed tumor growth, reduced M2 TAMs polarization, and enhanced CD8<sup>+</sup> T cell-mediated anti-tumor immunity.<h4>Conclusion</h4>Our findings revealed that NPM1 protects against tumor progression by regulating TAMs polarization and T cell function via the STAT3-CCRL2 axis.
Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1748791 · PubMed 42559137.
Why it matters for pharma & biotech
- Relevant to Immunology teams tracking Frontiers in Immunology for new targets, mechanisms and biomarkers.
- As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
- The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.
Frequently asked questions
What did this Frontiers in Immunology study find?
Overexpression of <i>Npm1</i> in mice suppressed tumor growth, reduced M2 TAMs polarization, and enhanced CD8<sup>+</sup> T cell-mediated anti-tumor immunity.<h4>Conclusion</h4>Our findings revealed that NPM1 protects against tumor progression by regulating TAMs polarization and T cell function via the STAT3-CCRL2 axis.
What type of study is this?
It is a preclinical (animal / model) study, published in Frontiers in Immunology in 2026. Here, we examined the function of NPM1 in regulating anti-tumor immunity within the tumor microenvironment.<h4>Methods</h4>The proportion and functional changes of macrophages and T cells were detected by flow cytometry, the downstream regulatory genes of <i>NPM1</i> were detected by RNA-seq, the binding ability of NPM1 and STAT3 was analyzed by Chip and luciferase assay.<h4>Results</h4>NPM1 inhibition or genetic deficiency promoted tumor growth in MC38 colon cancer and LLC lung cancer mice models.
Where can I read the original paper?
The original is at the publisher via DOI 10.3389/fimmu.2026.1748791. PubMed ID: 42559137. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/macrophage-npm1-drives-anti-tumor-immunity-via-the-stat3-ccrl2-axis-748791/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides